Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Capricor Therapeutics, Inc. (CAPR : NSDQ)
 
 • Company Description   
Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California.

Number of Employees: 160

 
 • Price / Volume Information   
Yesterday's Closing Price: $10.02 Daily Weekly Monthly
20 Day Moving Average: 3,176,034 shares
Shares Outstanding: 45.68 (millions)
Market Capitalization: $457.68 (millions)
Beta: 0.82
52 Week High: $23.40
52 Week Low: $3.52
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -18.80% -22.15%
12 Week 6.60% -6.59%
Year To Date -27.39% -31.42%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
10865 Road to the Cure Suite 150
-
San Diego,CA 92121
USA
ph: 858-727-1755
fax: 415-875-7075
info@capricor.com http://www.capricor.com
 
 • General Corporate Information   
Officers
Linda Marban - Chief Executive Officer;President and Director
Frank Litvack - Executive Chairman and Director
Anthony J. Bergmann - Chief Financial Officer
Earl M. Collier - Director
David B. Musket - Director

Peer Information
Capricor Therapeutics, Inc. (BJCT)
Capricor Therapeutics, Inc. (CADMQ)
Capricor Therapeutics, Inc. (APNO)
Capricor Therapeutics, Inc. (UPDC)
Capricor Therapeutics, Inc. (IMTIQ)
Capricor Therapeutics, Inc. (CYGN)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 14070B309
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 08/06/25
Share - Related Items
Shares Outstanding: 45.68
Most Recent Split Date: 6.00 (0.10:1)
Beta: 0.82
Market Capitalization: $457.68 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.19 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.03 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/06/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 3.59
Price/Cash Flow: -
Price / Sales: 20.55
EPS Growth
vs. Year Ago Period: -70.97%
vs. Previous Quarter: -231.25%
Sales Growth
vs. Year Ago Period: -7.92%
vs. Previous Quarter: 392.09%
ROE
06/30/25 - -
03/31/25 - -62.42
12/31/24 - -66.43
ROA
06/30/25 - -
03/31/25 - -48.36
12/31/24 - -46.10
Current Ratio
06/30/25 - -
03/31/25 - 6.55
12/31/24 - 7.77
Quick Ratio
06/30/25 - -
03/31/25 - 6.55
12/31/24 - 7.77
Operating Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -181.71
Net Margin
06/30/25 - -
03/31/25 - -
12/31/24 - -181.71
Pre-Tax Margin
06/30/25 - -
03/31/25 - -317.12
12/31/24 - -181.71
Book Value
06/30/25 - -
03/31/25 - 2.79
12/31/24 - 3.20
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - -
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©